Overview

Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and effectiveness of the combination of docetaxel and ZD1839 on destroying prostate cancer before removal of the prostate.
Phase:
Phase 2
Details
Lead Sponsor:
Benaroya Research Institute
Collaborators:
AstraZeneca
Sanofi
Treatments:
Docetaxel
Gefitinib